Nurse-Led Strategy to Improve Blood Pressure and Cholesterol Level Among People With HIV
Male
Infant, Newborn
Blood Pressure
Middle Aged
Atherosclerosis
Nurse's Role
03 medical and health sciences
0302 clinical medicine
Cardiovascular Diseases
Hypertension
Humans
Female
Original Investigation
Aged
DOI:
10.1001/jamanetworkopen.2023.56445
Publication Date:
2024-03-05T16:16:23Z
AUTHORS (12)
ABSTRACT
Importance Despite higher atherosclerotic cardiovascular disease (ASCVD) risk, people with HIV (PWH) experience unique barriers to ASCVD prevention, such as changing models of primary care. Objective To test whether a multicomponent nurse-led strategy would improve systolic blood pressure (SBP) and non–high-density lipoprotein (HDL) cholesterol level in diverse population PWH receiving antiretroviral therapy (ART). Design, Setting, Participants This randomized clinical trial enrolled at 3 academic clinics the US from September 2019 January 2022 conducted follow-up for 12 months until 2023. Included patients were 18 years or older had confirmed diagnosis, an HIV-1 viral load less than 200 copies/mL, both hypertension hypercholesterolemia. stratified by site 1:1 either EXTRA-CVD (A Nurse-Led Intervention Extend Treatment Cascade Cardiovascular Disease Prevention) intervention group control group. Primary analyses according intention-to-treat principle. The received home BP monitoring guidance management dedicated prevention nurse 4 in-person visits (baseline 4, 8, months) frequent telephone check-ins up every 2 weeks needed. general education sessions each visits. Main Outcomes Measures Study-measured SBP was outcome, non–HDL secondary outcome. Measurements taken over assessed linear mixed models. Prespecified moderators tested sex birth, baseline site. Results A total 297 arm (n = 149) 148). median (IQR) age 59.0 (53.0-65.0) included 234 males (78.8%). Baseline mean (SD) 135.0 (18.8) mm Hg 139.9 (44.6) mg/dL. At months, participants clinically significant 4.2-mm (95% CI, 0.3-8.2 Hg; P .04) lower 16.9-mg/dL 8.6-25.2 mg/dL; < .001) compared arm. There meaningful but not statistically difference effect females (11.8–mm greater 9.6 8 5.9 months; overall joint .06). Conclusions Relevance this indicate that effectively reduced should inform future implementation multifaceted programs PWH. Trial Registration ClinicalTrials.gov Identifier: NCT03643705
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (31)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....